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Summary
 
Synthetic oligodeoxynucleotides (ODN) that contain unmethylated CpG motifs (CpG ODN)
induce macrophages to secrete IL-12, which induces interferon (IFN)-
 
g
 
 secretion by natural
killer (NK) cells. Since these cytokines can induce T helper 1 (Th1) differentiation, we exam-
ined the effects of coadministered CpG ODN on the differentiation of Th responses to hen egg
lysozyme (HEL). In both BALB/c (Th2-biased) and B10.D2 (Th1-biased) mice, immunization
with HEL in incomplete Freund’s adjuvant (IFA) resulted in Th2-dominated immune re-
sponses characterized by HEL-specific secretion of IL-5 but not IFN-
 
g
 
. In contrast, immuniza-
tion with IFA-HEL plus CpG ODN switched the immune response to a Th1-dominated cy-
tokine pattern, with high levels of HEL-specific IFN-
 
g
 
 secretion and decreased HEL-specific
IL-5 production. IFA-HEL plus CpG ODN also induced anti-HEL IgG2a (a Th1-associated
isotype), which was not induced by IFA-HEL alone. Control non–CpG ODN did not induce
IFN-
 
g
 
 or IgG2a, excepting lesser increases in B10.D2 (Th1-biased) mice. Thus, CpG ODN
provide a signal to switch on Th1-dominated responses to coadministered antigen and are po-
tential adjuvants for human vaccines to elicit protective Th1 immunity.
 
A
 
ntigen-specific CD4
 
1
 
 Th cell responses can be di-
vided into two types, type 1 and type 2, based upon
cytokine secretion and effector function (1–3). Type 1 re-
sponses involve Th1 cells, whose differentiation is driven
by IL-12 (from macrophages) and IFN-
 
g
 
 (from NK cells or
T cells). Th1 cells secrete cytokines such as IFN-
 
g
 
, IL-2,
and lymphotoxin. In turn, IFN-
 
g
 
 activates macrophages and
enhances immunoglobulin isotype switching to IgG2a, a
hallmark of Th1 immunity (4). In contrast, type 2 responses
involve IL-4–dependent differentiation of Th2 cells, which
produce IL-4, IL-5, IL-10, and IL-13. Type 2 responses are
associated with decreased macrophage activation, since some
Th2-associated cytokines depress certain macrophage func-
tions. The Th1/Th2 model provides a useful conceptual
framework for Th differentiation, and the existence of dis-
tinct type 1 and type 2 responses is clearly established, al-
though certain aspects of the model require further investi-
gation (5). Moreover, differential induction of type 1 or
type 2 responses is required for protective immunity to cer-
tain infectious diseases, and induction of the wrong re-
sponse type can increase susceptibility to infection (see Dis-
cussion). Thus, the type of response induced by a vaccine
may be crucial to its efficacy.
 
The type of Th response generated to an administered
antigen can be directed by the type of adjuvant used. Injec-
tion of antigen in CFA induces a Th1-dominated response
to the antigen, while injection of antigen in IFA induces a
Th2-dominated response (6). However, because of its un-
desirable inflammatory side effects, CFA is not suited for
use in human vaccines. Since type 1 immunity plays an im-
portant role in the protective response to infection with
certain microbes, it is now important to characterize other
novel adjuvants that safely induce type 1 immunity and that
may potentially be incorporated in future human vaccines.
The recent discovery that certain DNA preparations affect
cytokine expression by cells of the innate immune system
suggests the possibility that DNA preparations could be
used as adjuvants to influence the differentiation of Th re-
sponses.
The ability of DNA to induce expression of cytokines
depends on its source and characteristics (7). In vitro, bac-
terial DNA induces macrophage expression of IL-12 (8)
and TNF-
 
a
 
 (9), which are not induced by mammalian
DNA. Bacterial DNA also indirectly activates NK cells and
stimulates their production of IFN-
 
g
 
 
 
(10–12), since NK
cell production of IFN-
 
g
 
 is triggered by IL-12 that is gen-
erated by macrophages in response to bacterial DNA (8, 13).
To define components of bacterial DNA that have im-
munomodulatory effects, a panel of synthetic oligodeoxy-
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nucleotides (ODN)
 
1
 
 was used to identify specific 6-base pair
sequences that conferred activity (14). These sequences
shared a CpG motif, containing a central unmethylated CpG
dinucleotide preferentially flanked by two 5
 
9
 
 purines and
two 3
 
9
 
 pyrimidines. CpG dinucleotides are present in bac-
terial DNA at the expected frequency of 1/16 bases, but
they are three- to fourfold less frequent in mammalian DNA,
a phenomenon known as CpG suppression (15). Also, the
cytosines in CpG dinucleotides in mammalian DNA are
highly methylated, whereas those in bacterial DNA are not
(15). Elimination of the CpG sequence or methylation of
the cytosine abrogates the stimulatory activity of ODN
containing CpG motifs (CpG ODN) and bacterial DNA
(9, 11, 14).
When added to splenocytes in culture, CpG ODN in-
duce production of the Th1-associated cytokines IFN-
 
g
 
 and
IL-12, as well as the Th2-associated cytokine, IL-6, within
several hours (16). However, production of other Th2-asso-
ciated cytokines, such as IL-4, IL-5, and IL-10, is not de-
tected. The rapid production of IFN-
 
g
 
 is mediated by NK
cells stimulated by IL-12 secretion from CpG-activated
macrophages; this initial phase of IFN-
 
g
 
 production does not
require T cells (8, 13). The induction of IFN-
 
g
 
 and IL-12
(which promote Th1 responses), but not IL-4 (which pro-
motes Th2 responses), suggests that administration of CpG
ODN in vivo might produce an environment favoring a Th1
immune response. Indeed, some bacterial plasmid DNA vac-
cines, which contain this CpG motif, cause development of
antigen-specific CD4
 
1
 
 splenocytes that secrete IFN-
 
g
 
, but
not IL-4 or IL-5 (17, 18).
The effect of CpG ODN on antigen-specific T cell re-
sponses has not been previously tested. Our current experi-
ments directly test the hypothesis that CpG ODN may
serve as adjuvants to switch on Th1 responses. While im-
munization with hen egg lysozyme (HEL) in IFA induced
a Th2-dominated response to HEL, immunization with
IFA-HEL plus CpG ODN induced a strongly Th1-domi-
nated response to HEL, as measured by production of spe-
cific IgG2a antibody and production of IFN-
 
g
 
 by antigen-
stimulated T cells. We propose that CpG ODN function as
adjuvants that switch on Th1 responses, making them im-
portant candidate adjuvants for potential use in future hu-
man vaccines.
 
Materials and Methods
 
Oligodeoxynucleotides.
 
ODN were purchased from Operon
Technologies (Alameda, CA) or Oligos Etc. (Wilsonville, OR).
ODN were phosphorothioate-modified to increase their resis-
tance to nuclease degradation. ODN used in these studies are
listed in Table 1 and their sequences are given here (CpG motifs
or reversed non-CpG motifs are underlined). Sequences of ODN
that were phosphorothioate-modified throughout (S ODN) are:
CpG ODN 1826, TCCATGACGTTCCTGACGTT; non–CpG
ODN 1745, TCCAATGAGCTTCCTGAGTCT; CpG ODN
1760, ATAATCGACGTTCAAGCAAG; non–CpG ODN 1908,
ATAATAGAGCTTCAAGCAAG. Sequences of ODN phos-
phorothioate-modified on the ends only (S-O ODN) are: CpG
ODN 1585, GGGGTCAACGTTGAGGGGGG; and non–CpG
ODN 1972, GGGGTCTGTGCTTTTGGGGGG. The first two
5
 
9
 
 end bonds and last five 3
 
9
 
 end bonds of the S-O ODN are
phosphorothioate-modified. Synthetic ODN were dissolved in
TE (10 mM Tris, 1 mM EDTA). LPS content of ODN was 
 
,
 
1
ng LPS/mg DNA, as measured by Limulus amebocyte assay
(QCL-1000; BioWhittaker, Walkersville, MD).
 
Immunizations.
 
BALB/c and B10.D2 mice (Jackson Labora-
tory, Bar Harbor, ME and Harlan Sprague Dawley, Indianapolis,
IN) were housed in microisolators under specific pathogen-free
conditions and injected at 7–12 wk of age. HEL (Sigma Chem.
Co., St. Louis, MO) was dissolved in PBS, ODN were dissolved
in TE, and LPS (
 
E. coli
 
 0127:B8; Difco, Detroit, MI) was dis-
solved in PBS. ODN were added to HEL in a volume less than
10% of the final volume. HEL solutions with or without ODN or
LPS were combined with IFA (GIBCO BRL, Gaithersburg, MD)
at a 1:1 (vol/vol) ratio and emulsified to achieve a final HEL con-
centration of 1 mg/ml. CFA was prepared by suspending 
 
Myco-
bacterium tuberculosis
 
 H37 RA (Difco) at 4 mg/ml in IFA, and
CFA was emulsified with the HEL solutions as above. Groups of
three mice were injected i.p. with 200 
 
m
 
l of an emulsion and
killed 3 wk after injection.
 
ELISA Assay for Antigen-specific Antibody Production.
 
Sera were
collected from mice by tail bleed 3–4 d before sacrifice (15–18 d
after immunization with HEL), then diluted 1:10 in PBS/0.2%
sodium azide and stored at 
 
2
 
20
 
8
 
C. For ELISA, Nunc brand 96-
well immunoplates (Fisher, Pittsburgh, PA) were coated by over-
night incubation at 4
 
8
 
C with HEL at 10 
 
m
 
g/ml in 0.1 M sodium
bicarbonate buffer. Plates were washed and blocked with PBS with
0.05% Tween (PBST) containing 0.1% gelatin for 1–2 h at room
temperature. Sera were added to the top row of each plate and
serial 1:3 dilutions in PBS were then made into subsequent rows.
The plates were incubated overnight at 4
 
8
 
C and washed. Alkaline
phosphatase-conjugated detecting antibody was added in PBST/
0.1% gelatin and incubated for 2 h at room temperature. For
IgG1 and IgG2a detection, goat anti–mouse IgG1 or IgG2a
(Southern Biotechnology Associates, Birmingham, AL) was used
at 1:4,000. For total Ig detection, goat anti–mouse Ig(H
 
1
 
L) (South-
ern Biotechnology Associates), specific for IgM 
 
1
 
 IgG 
 
1
 
 IgA,
was used at 1:2,000. The colorimetric assay was developed with
para-nitrophenyl phosphate (50 mg/ml in 2.5 M sodium bicar-
bonate/2.5 M magnesium chloride buffer) for 1–3 h. Absorbance
at 405 nm was determined using a Beckman Bio Tek Microplate
Autoreader (EL309; Beckman Instruments, Palo Alto, CA). The
serum from each mouse was assayed in duplicate and the mean
value was used to represent each animal. These values were used
to calculate the mean and standard deviation for each group of
three mice.
 
ELISA Spot Assay for Cytokine Production.
 
Splenocytes were iso-
lated from mice 3 wk after immunization. A modified ELISA spot
assay for detection of cytokine production by splenocytes has
been developed in prior work (6). ELISA spot plates (Polyfiltron-
ics, Rockland, MA) were coated with capture antibody for IFN-
 
g
 
(R46A2; 4 
 
m
 
g/ml in PBS) or IL-5 (TRFK5; 5 
 
m
 
g/ml in PBS)
overnight at 4
 
8
 
C. Plates were then washed and blocked with
PBS/1% BSA for 1–2 h at room temperature. After washing,
freshly isolated splenocytes were plated at 10
 
6
 
 cells/well in se-
rum-free medium, HL-1 (BioWhittaker), supplemented with
 
1
 
Abbreviations used in this paper:
 
 HEL, hen egg lysozyme; ODN, oligode-
oxynucleotides; PBST, PBS with Tween; S ODN, phosphorothioate-
modified ODN; S-O ODN, ODN with partial phosphorothioate modifi-
cation. 
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L
 
-glutamine and penicillin/streptomycin, in the presence or ab-
sence of HEL (100 
 
m
 
g/ml). In some experiments purified GK1.5
anti-CD4 antibody (American Type Culture Collection, Rockville,
MD) was added at 10–30 
 
m
 
g/ml to block CD4 T cell function.
After culture for 24 h (for IFN-
 
g
 
 detection) or 48 h (for IL-5 de-
tection), cells were removed by washing with PBS and then
PBST. Detecting antibody (XMG1.2-HRP, 1:400 for IFN-
 
g
 
;
TRFK4, 4 
 
m
 
g/ml for IL-5) was added in PBST/1% BSA and in-
cubated overnight. For the IL-5 assay only, anti–IgG2a-HRP
(Zymed, South San Francisco, CA) was added after washing with
PBST, and the plates were incubated for 2 h at room tempera-
ture. All plates were washed with PBS before developing the col-
orimetric assay by the addition of 1% 3–amino-9-ethylcarbazole/
 
N
 
,
 
N
 
-dimethylformamide in 0.1 M sodium acetate buffer (1:30
vol/vol) for 45–60 min. The plates were then washed with dis-
tilled water and air dried. Spots were quantitated by an image
analysis program (Optimas, Bothell, WA).
 
Results
 
Coadminstered CpG ODN Induce Production of HEL-specific
IgG2a (a Th1-associated Isotype).
 
BALB/c mice were in-
jected i.p. with 200 
 
m
 
g of HEL in the following adjuvants:
CFA, IFA, IFA with CpG ODN 1826, or IFA with a sim-
ilar ODN lacking the CpG motif, ODN 1745. ODN 1826
and ODN 1745 are phosphorothioate-modified for the en-
tire length of the backbone (S ODN; see Table 1), which
greatly increases resistance to nuclease degradation (19).
Based on preliminary dose titration studies, ODN were ini-
tially used at 100 
 
m
 
g/mouse. Sera were collected 15–18 d
after immunization and assayed for anti-HEL Ig (total or
specific isotype) by ELISA. Consistent with previous results
demonstrating that IFA induces a Th2 response while CFA
induces a Th1 response to antigen (6), mice injected with
IFA-HEL did not produce detectable IgG2a responses (Fig.
1 
 
A
 
). In contrast, mice injected with CFA-HEL produced
high levels of IgG2a. The addition of non–CpG ODN
1745 to the IFA-HEL protocol did not induce IgG2a pro-
duction. However, immunization with IFA-HEL-CpG
ODN 1826 altered the isotype profile of the antibody re-
sponse, causing a marked increase in anti-HEL IgG2a. Fur-
thermore, in three independent experiments, the produc-
tion of HEL-specific IgG2a was consistently higher in mice
treated with IFA-HEL-CpG ODN 1826 than in mice
treated with CFA-HEL.
Despite the changes in IgG2a responses, similar levels of
anti-HEL IgG1 or total anti-HEL Ig were produced by all
immunizations (Fig. 1, 
 
B
 
 and 
 
C
 
). Thus, immunization with
IFA-HEL or IFA-HEL–non-CpG ODN 1745 was success-
ful and sufficient to generate an antibody response to HEL,
with both anti-HEL IgG1 and total anti-HEL Ig levels
comparable to those seen with CFA-HEL or IFA-HEL-
CpG ODN 1826. Although the IgG1 isotype has been
linked to Th2 responses, our data demonstrate that IgG1
can also be observed in Th1-dominated responses and, at
least in this system, cannot be used to accurately assess Th
differentiation. We conclude that the increased IgG2a pro-
duction associated with IFA-HEL-CpG ODN 1826, like
that caused by CFA-HEL, represents a selective induction
of this isotype, i.e., a qualitative switch in the relative levels
of antibody isotypes produced rather than a simple en-
hancement of all anti-HEL isotypes.
 
Table 1.
 
Sequences of Synthetic ODN
 
ODN Sequence
 
*
 
Motif Backbone
 
¯¯ ¯¯
 
1826
 
TCCATGACGTTCCTGACGT
 
T
 
CpG S ODN
1745
 
TCCAATGAGCTTCCTGAGTC
 
T
 
non-CpG S ODN
 
¯¯ ¯¯
 
1760
 
ATAATCGACGTTCAAGCAA
 
G
 
CpG S ODN
1908
 
ATAATAGAGCTTCAAGCAA
 
G
 
non-CpG S ODN
 
¯¯
 
1585
 
GG
 
GGTCAACGTTGA
 
GGGGG
 
G
 
CpG S-O ODN
1972
 
GG
 
GGTCTGTGCTTTT
 
GGGGG
 
G
 
non-CpG S-O ODN
Nucleotides that have their 3
 
9
 
 linkage phosphorothioate modified to
increase resistance to nuclease degradation are in bold print.
 
*
 
The CpG motifs or corresponding non-CpG motifs are underlined.
Figure 1. Th1-associated antigen-specific IgG2a responses are induced
by immunization of BALB/c mice with IFA-HEL-CpG ODN but not
IFA-HEL-non–CpG ODN. (A–C). Mice were injected i.p. with CFA-
HEL (a control for a Th1-dominated response), IFA-HEL (a control for a
Th2-dominated response), or IFA-HEL with 100 mg of CpG ODN 1826
or non–CpG ODN 1745. Sera were collected from mice 15–18 d after
injection and assayed by ELISA for: (A) anti-HEL IgG2a, an isotype asso-
ciated with Th1-dominated responses; (B) anti-HEL IgG1; and (C) anti-
HEL total Ig response. A–C represent data from a single experiment rep-
resentative of three similar experiments. (D) BALB/c mice were immu-
nized as above, except that 30 mg of CpG ODN 1585, non–CpG ODN
1972, CpG ODN 1760, or non–CpG ODN 1908 was used for each
mouse. Anti-HEL IgG2a antibodies were detected by serum ELISA. Data
shown in D are representative of three similar experiments. 
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To confirm the role of the CpG motif, we also exam-
ined the effects of two additional pairs of CpG and non–
CpG ODN. CpG ODN 1760 and a related non-CpG con-
trol, ODN 1908, are S ODN (Table 1). CpG ODN 1585
and a related non-CpG control, ODN 1972, are phospho-
rothioate-modified on the ends only (S-O ODN; see Table
1). ODN 1760 and ODN 1826 share a common CpG mo-
tif, GACGTT. Immunization of BALB/c mice with HEL
in IFA with or without 30 mg of each ODN showed that
both CpG ODN (ODN 1760 and ODN 1585) induced
anti-HEL IgG2a antibodies, which were not induced by
the non–CpG ODN (ODN 1908 and ODN 1972) (Fig. 1
D). The S ODN 1760 induced significantly higher levels of
anti-HEL IgG2a than CFA or the S-O ODN 1585 (which
is more nuclease-sensitive than ODN 1760). Anti-HEL
IgG1 and total anti-HEL Ig responses were similar in all
groups (data not shown), again indicating that all of the im-
munizations generated anti-HEL antibody responses of
similar overall magnitude. We conclude that antigen-spe-
cific IgG2a antibodies are induced by CpG ODN, suggest-
ing that CpG ODN induce a Th1-dominated response to
coadministered protein antigen.
Coadministration of CpG ODN Induces Th1-dominated An-
tigen-specific Cytokine Responses. We used a modified ELISA
spot assay (see Materials and Methods) to assess recall anti-
gen-specific IFN-g secretion as a measure of Th1 memory
cells induced after immunization with HEL. Three weeks af-
ter immunization of BALB/c mice with HEL in adjuvant,
splenocytes were isolated, incubated in vitro with or
without HEL and assayed for IFN-g production. Upon re-
stimulation with HEL, splenocytes from mice immunized
with IFA-HEL showed little or no antigen-specific pro-
duction of IFN-g (Fig. 2 A), as expected (6). In contrast,
splenocytes from mice immunized with CFA-HEL showed
antigen-specific production of IFN-g, demonstrating that
CFA-HEL induced a Th1 response to HEL in these mice,
as previously observed (6). Prior studies using isolated spleen-
derived CD41 T cells (with irradiated BALB/c-scid sple-
nocytes as antigen-presenting cells) have shown that anti-
gen-specific cytokine secretion measured by this assay is
mediated by CD41 T cells (Yip, H., A. Karulin, M. Tary-
Lehmann, P. Heeger, R. Trezza, T. Forsthuber, and P.V.
Lehmann, manuscript submitted for publication).
The results obtained with ODN established an important
role for the CpG motif in determining Th differentiation.
Immunization with IFA-HEL-non–CpG ODN 1745 did
not enhance antigen-specific IFN-g production over that
observed with IFA-HEL. In contrast, immunization with
IFA-HEL-CpG ODN 1826 strongly induced the produc-
tion of antigen-specific cells secreting IFN-g (Figs. 2 A and
3). Immunization with IFA-HEL-CpG ODN 1826 pro-
duced two- to fourfold more antigen-specific IFN-g secre-
tion than observed with CFA-HEL (Fig. 2 A and data not
shown).
To determine the dose range for effective Th1 adjuvant
activity of CpG ODN 1826, BALB/c mice were injected
i.p. with 200 mg HEL in IFA, together with 0, 10, 30, or
100 mg ODN 1826. Antigen-specific serum Ig levels were
assayed as above. Production of anti-HEL IgG2a was
strongly enhanced in mice treated with as little as 10 mg
ODN 1826, while specific production of total Ig and IgG1
was not affected by ODN 1826 at any dose (data not
shown). ELISA spot analysis of splenocytes from these mice
showed strong induction of IFN-g by 30 or 100 mg ODN
1826 and lesser enhancement with only 10 mg (data not
shown). Thus, Th1-directing adjuvant activity of CpG ODN
is seen with doses as low as 10 mg in BALB/c mice.
To confirm that the Th1 adjuvant activity of CpG ODN
1826 was specific to the CpG motif, other CpG and non–
CpG ODN were examined for effects on the differentia-
tion of the Th response to HEL. As demonstrated in Fig.
2 B, immunization with both of the additional CpG ODN
(ODN 1760 and ODN 1585) increased the number of cells
secreting IFN-g in response to secondary stimulation with
HEL, while little or no increase was seen with the non–
CpG ODN (ODN 1972 and ODN 1908). Consistent with
the pattern of IgG2a induction, the S ODN 1760 appeared
to have a greater effect than the S-O ODN 1585 on in-
creasing numbers of IFN-g–secreting cells. Thus, the num-
ber of cells secreting IFN-g is enhanced by CpG ODN but
not by non–CpG ODN, supporting the induction of Th1-
dominated responses by CpG ODN. Furthermore, the ad-
dition of anti-CD4 antibody (GK1.5 at 10–30 mg/ml) during
the in vitro antigen stimulation blocked CpG ODN-enhanced,
HEL-specific IFN-g secretion (data not shown), confirm-
ing that the CpG ODN-enhanced production of IFN-g
was T cell–dependent in this system.
To assess Th2 differentiation, ELISA spot analysis was
similarly performed to detect splenocytes producing IL-5
(Fig. 4). Immunization with IFA-HEL induced cells that
secreted IL-5 in response to restimulation with HEL, con-
sistent with a Th2-dominated response. In contrast to the
results with IFA-HEL, little or no HEL-specific IL-5 secre-
tion was seen in mice immunized with CFA-HEL, consis-
tent with a Th1-dominated anti-HEL response in these
mice. HEL-specific IL-5 secretion was observed after im-
Figure 2. CpG ODN en-
hance HEL-specific IFN-g pro-
duction by BALB/c splenocytes.
Mice were immunized as in Fig.
1 with 100 mg ODN/mouse in
A and 30 mg ODN/mouse in
panel B. After 3 wk, splenocytes
were isolated and incubated with
HEL (closed circles) or medium
alone (open circles). ELISA spot
assay was performed and spots
were quantitated by a computer-
ized image analysis program.
Each point represents the mean
number of spots per well for one
mouse (assayed in duplicate);
horizontal bars indicate the mean
of points for each group of mice.
Similar results were observed in
five independent experiments
with CpG- and non–CpG ODN
in BALB/c mice.1627 Chu et al.
munization with IFA-HEL-non–CpG ODN (e.g., ODN
1745 and ODN 1972), although immunization with IFA-
HEL-non–CpG ODN 1745 produced somewhat lower
levels of IL-5 than observed with IFA-HEL. In contrast,
greater reduction in HEL-specific IL-5 secretion was ob-
served after immunization with CpG ODN (ODN 1826,
ODN 1760 and ODN 1585). Thus, the addition of CpG
ODN induced a switch from a Th2-dominated response to
a Th1-dominated response, as manifested by a decrease in
Th2-associated cytokine secretion as well as the induction
of Th1-associated cytokine secretion.
Together, these results indicate that CpG ODN directed
Th1 differentiation in the T cell responses to coadminstered
antigen. Relative to immunization with IFA-HEL, im-
munization with IFA-HEL-CpG ODN increased HEL-
specific IFN-g production by splenocytes, decreased HEL-
specific IL-5 production by splenocytes and increased IgG2a
anti-HEL titers. Furthermore, the Th1 adjuvant activity of
CpG ODN for both antigen-specific antibody and cyto-
kine production was significantly greater than that of an es-
tablished Th1 adjuvant, CFA.
CpG ODN Direct Th1-dominated Responses in Th1-biased
(B10.D2) Mice as well as Th2-biased (BALB/c) Mice.
Strains of mice differ in genetic bias toward the develop-
ment of Th1- or Th2-dominated Th responses. Earlier pub-
lications have demonstrated that BALB/c mice are Th2-
biased, while B10.D2 mice are more Th1-biased (20). To
explore the impact of varying Th1/Th2 bias on the effect
of CpG ODN, B10.D2 mice were injected i.p. with IFA-
HEL, with or without 30 mg CpG ODN 1826 or non–CpG
ODN 1745, and splenocytes were subsequently isolated
for ELISA spot analysis. Immunization with IFA-HEL-CpG
ODN 1826 produced a very high level of HEL-specific
IFN-g production, while IFN-g was not produced after
immunization with IFA-HEL alone (Fig. 5). Again, CpG
ODN 1826 induced levels of HEL-specific IFN-g production
that exceeded even those seen after immunization with
CFA-HEL, and augmentation of IFN-g production, albeit
at lower levels, was seen in B10.D2 mice treated with as
little as 3 mg of ODN 1826 in IFA-HEL (data not shown).
Immunization with IFA-HEL plus either of the two other
CpG ODN, ODN 1760, and ODN 1585, also induced
HEL-specific secretion of IFN-g (data not shown). Immu-
nization with the non–CpG ODN 1745 and 1908 (30 mg
dose) induced HEL-specific production of IFN-g by sple-
nocytes from B10.D2 mice, but at a minimal level (Fig. 5
and data not shown), while the other non–CpG ODN,
ODN 1972, did not induce IFN-g (data not shown). Thus,
CpG ODN had strong Th1 adjuvant activity in Th1-biased
as well as Th2-biased mice, while non–CpG ODN induced
little or no Th1 differentiation, as assessed by antigen-specific
secretion of IFN-g.
The effects of CpG ODN on IFN-g responses were par-
alleled by changes in IgG2a levels in B10.D2 mice. Again,
immunization with IFA-HEL-CpG ODN 1826 (3, 10, or
30 mg ODN) induced high titers of anti-HEL IgG2a, and
similar results were seen with the other CpG ODN, ODN
Figure 3. ELISA spot assess-
ment of IFN-g production by
splenocytes from immunized
BALB/c mice. Pictures show
representative images of ELISA
spot wells from the experiment
shown in Fig. 2 A. The number
of spots, as quantitated by an im-
age analysis program, is indicated
next to each well. Each well
contained HEL (100 mg/ml) and
106 splenocytes isolated from
mice immunized with IFA-HEL
(A), IFA-HEL-non–CpG ODN
1745 (B) or IFA-HEL-CpG
ODN 1826 (C).
Figure 4. CpG ODN de-
crease HEL-specific IL-5 pro-
duction by BALB/c splenocytes.
Mice were immunized as in Fig.
2 (30 mg ODN/mouse), and
splenocytes were harvested for in
vitro restimulation with or with-
out HEL. ELISA spot analysis
was performed for IL-5. The
data are representative of five
similar experiments with CpG-
and non–CpG ODN in BALB/c
mice.
Figure 5. Induction of HEL-
specific IFN-g responses by CpG
ODN in B10.D2 mice. B10.D2
mice were immunized as in Fig.
1, except that ODN were used
at 30 mg per mouse. Three
weeks after immunization, HEL-
specific production of IFN-g by
splenocytes was measured by
ELISA spot assay as in Fig. 2.
The data shown are representa-
tive of three similar experiments.1628 CpG DNA as a Th1 Adjuvant
1760, and ODN 1585 (only the 30 mg dose was assessed,
data not shown). Mice treated with 30 mg non–CpG ODN
1745 also produced anti-HEL IgG2a, though the levels
were not as high as in mice treated with ODN 1826, but
the other non–CpG ODN (ODN 1908 and ODN 1972)
did not induce IgG2a production. Anti-HEL total Ig and
IgG1 levels were similar under all of these conditions (data
not shown). These results confirm that CpG ODN en-
hance Th1-associated antigen-specific IgG2a responses in
both Th1- and Th2-biased mouse strains.
Discussion
Because it is highly effective in inducing both cellular
and humoral immunity, CFA has been an important model
adjuvant (21). Furthermore, CFA has been shown to in-
duce Th1-dominated immune responses (6). However, due
to its inflammatory side effects, CFA cannot be used in hu-
mans. Thus, the discovery and characterization of adjuvants
that promote Th1 cell–mediated immunity is currently an
important area in vaccine development. Our results estab-
lish that CpG ODN are excellent candidate adjuvants for
vaccines to induce Th1 immunity.
CFA is prepared by mixing two components, IFA (min-
eral oil) and nonviable Mycobacterium tuberculosis. As an ad-
juvant, CFA has been proposed to provide two crucial
functions. First, it creates a local antigen depot (by entrap-
ment of antigen in the mineral oil emulsion) which allows
for prolonged regional antigenic stimulation. This function
is also provided by IFA. Second, CFA contains immuno-
modulatory substances derived from Mycobacterium tuberculo-
sis that stimulate immune responses and promote Th1 dif-
ferentiation. It is possible that the adjuvant activity of CFA
may be due in part to mycobacterial DNA, as M. bovis
DNA sequences have been shown to be immunostimula-
tory (22, 23). Thus, a general strategy for the development
of type 1 vaccine adjuvants may be to provide both an anti-
gen depot and an immunomodulatory function that pro-
motes Th1 differentiation.
Our studies address the ability of CpG ODN to modu-
late the differentiation of Th responses. In these experi-
ments, ODN were mixed with IFA, which itself establishes
an antigen depot but does not promote Th1 differentiation
(future vaccines using CpG ODN may include alternative
components such as biodegradable oils to optimize vaccine
safety and efficacy). Mice that were immunized with IFA-
HEL developed both humoral and Th2 cellular immune
responses, consistent with prior observations (6). However,
the addition of CpG ODN to this system induced strong
Th1-dominated responses. Th1-dominated responses were
induced with as little as 3 mg CpG ODN in B10.D2 mice
and 10 mg CpG ODN in BALB/c mice.
As a direct measure of Th1 differentiation, we moni-
tored the number of splenocytes secreting IFN-g after im-
munization and in vitro stimulation with HEL by ELISA
spot assay. This assay has been shown to detect cytokine se-
cretion by individual CD41 T cells (Yip, H., A. Karulin,
M. Tary-Lehmann, P. Heeger, R. Trezza, T. Forsthuber,
and P.V. Lehmann, manuscript submitted for publication).
Also, addition of a blocking anti-CD4 mAb to the spleno-
cytes during in vitro stimulation with HEL decreased HEL-
specific production of IFN-g by .80% (data not shown),
confirming that the production of IFN-g was dependent
on antigen-specific CD41 T cells. We also measured IFN-g
production by standard ELISA and found the same pattern
of results as obtained by the ELISA spot assay (data not
shown).
The addition of CpG ODN as adjuvants produced levels
of IFN-g that surpassed even the levels observed with CFA.
Two of the non–CpG ODN (ODN 1745 and ODN 1908)
induced IFN-g secretion, but only at minimal levels and
only in Th1-biased B10.D2 mice. ODN 1745 also induced
production of antigen-specific IgG2a, although ODN 1908
did not. The slight CpG-like effects of ODN 1745 may be
due in part to the presence of TG dimers in a context that
provides a weak analogue of a CpG motif. Other studies
have shown that weak induction in vitro of other CpG-
like effects by ODN 1745 (B cell proliferation, secretion of
IL-6, TNF-a, and IL-12) are eliminated in analogues of
ODN 1745 that lack TG dimers (Krieg, A.M., unpublished
observations). In addition, weak CpG-like effects could be
triggered by the DNA backbone of non–CpG ODN (e.g.
ODN 1745 and ODN 1908), since the phosphorothioate
backbone of modified ODN has some intrinsic immuno-
stimulatory properties (7, 24). Despite minor activities of
some non–CpG ODN, the CpG ODN were vastly supe-
rior for inducing Th1-dominated immune responses in
both Th1- and Th2-biased mouse strains. These observa-
tions indicate that the CpG motif provides a strong and re-
liable stimulus for Th1 differentiation in animals of differ-
ing genetic background.
We also assessed the differentiation of Th responses indi-
rectly by the isotype profile of antigen-specific antibody re-
sponses. CpG ODN induced levels of antigen-specific
IgG2a that surpassed even those achieved with CFA. Total
anti-HEL Ig and anti-HEL IgG1 levels induced by CpG
ODN did not differ appreciably from those induced by IFA
or CFA, indicating that all of the immunization protocols
used in this study were successful and effective for genera-
tion of anti-HEL Ig. Thus, the increased production of
IgG2a induced by CpG ODN and CFA represents a quali-
tative switch in Ig isotype production from an IFA-induced
Th2-influenced pattern to a Th1-influenced pattern.
We assessed the differentiation of Th2 responses by anti-
gen-specific IL-5 production. Although IL-4 is also pro-
duced during Th2 responses, there can be differences in the
production and source of these two cytokines under some
circumstances. Even in the context of a Th1 response, anti-
gen-stimulated T cells can induce IL-4 (but not IL-5) se-
cretion by non–T cells (Karulin and Lehmann, unpublished
observations). Other groups have reported that treatment
with IL-12 at the time of immunization can induce antigen-
specific IL-4 production by splenocytes (25), again demon-
strating that IL-4 can be detected alongside markers of Th11629 Chu et al.
responses. Therefore we chose IL-5 secretion as a clear,
specific marker for Th2 differentiation in our studies, i.e., a
cytokine whose antigen-triggered secretion could be attrib-
uted to antigen-specific T cells. The differentiation of cells
secreting IL-5 was monitored by the ELISA spot assay. We
also tested the supernatants from similar incubations for IL-5
by standard ELISA, which revealed the same pattern of re-
sults (data not shown).
ELISA spot analysis demonstrated that HEL-specific IL-5
secretion was induced by immunization with IFA-HEL but
was absent after immunization with CFA-HEL. Immuniza-
tion with IFA-HEL-CpG ODN produced significantly
lower levels of IL-5 secretion than observed with IFA-
HEL. Thus, in addition to enhancing Th1 differentiation,
CpG ODN appear to at least partially switch off Th2 dif-
ferentiation to produce Th1-dominated immune responses.
Moreover, these studies examined Th differentiation after a
single immunization. It is possible that repeated administra-
tion of antigen with CpG ODN would produce an even
more polarized Th1 response.
The experiments shown here monitored IgG2a levels at
15-18 d after immunization and T cell responses at three
weeks after immunization. Additional experiments also ex-
amined cytokine responses upon antigenic restimulation of
T cells at 4 and 6 wk after immunization, as well as IgG2a
levels at 3–4 d before these times. At all of these time points
the exact same pattern of results was consistently found.
For example, CpG ODN produced enhanced IFN-g and
IgG2a responses in all experiments at these later time points
(data not shown). These results indicate that the pattern of
T cell differentiation induced by a single immunization
with CpG ODN remains stable for at least 6 wk.
The possibility that the effects of CpG ODN were due
to contaminating LPS was excluded by the following
observations. First, LPS levels in the ODN preparations
were very low (,,1 ng LPS/mg DNA). Second, we im-
munized with IFA-HEL plus LPS at 1 ng/mouse (an
amount 10–100-fold higher than the maximum amounts
contributed by the highest ODN doses) and failed to see
any increase in Th1-associated results (IFN-g secretion and
induction of IgG2a) or decrease in Th2-associated IL-5 se-
cretion (data not shown).
One concern for DNA adjuvants, as with all adjuvants, is
the potential for toxicity. The administration of bacterial
DNA or stimulatory ODN can induce TNF-a release and
fatal shock in mice that have been previously sensitized with
D-galactosamine (26), and CpG DNA can prime mice for
the Shwartzmann reaction (12). With regard to ODN ad-
juvants, mice given repeated high doses of CpG ODN de-
velop a dose-dependent splenomegaly and can develop
other toxicity related to excessive immune stimulation, in-
cluding death (27). However, significant toxicity has not
been observed at the low doses of ODN used for adjuvant
function in our current studies, where we observed no sig-
nificant changes in mouse appearance, behavior, and body
weight (measured at multiple points throughout the exper-
iment) or spleen weight (measured at the time of sacrifice).
We also noted that spleens from mice injected with CFA
were more difficult to remove, presumably due to post-
inflammatory peritoneal fibrosis, while spleens from mice
injected with CpG ODN appeared normal. Additional
studies of spleen and lymph node sizes at earlier time points
after administration of CpG ODN alone, at the doses used
here, revealed mild splenomegaly and hyperplasia of drain-
ing lymph nodes that was reversible within 10–14 d. Mice
injected with a single dose of up to 1 mg of the S ODN
used in these studies (100-fold higher than the effective ad-
juvant dose) showed no apparent systemic toxicity or change
in feeding, grooming, physical activity or behavior. We
conclude that CpG ODN provide potent adjuvant activity
at doses that produce no dangerous toxicity.
In the context of vaccine development, the ability to di-
rect Th1 or Th2 differentiation of antigen-specific immune
responses has significant implications for therapy of various
infectious and autoimmune diseases (28). In the case of cer-
tain infectious diseases, Th1-dominated immune responses
are protective, while Th2-dominated responses are associ-
ated with disease susceptibility. For example, in murine leish-
maniasis, Th2-biased mouse strains (e.g., BALB/c) make
IL-4–dominated responses to parasite antigens and are
susceptible, whereas mice that mount Th1-dominated re-
sponses involving IFN-g secretion (e.g., C57BL/6) are re-
sistant (29–31). Moreover, susceptible mice can be made
resistant by administration of IL-12 to enhance Th1 immu-
nity or antibody blockade of IL-4 (32-34), and resistant
mice can be made sensitive by blockade of IL-12 (35). In
similar circumstances in humans, the ability to direct vac-
cine-induced immunity towards Th1 responses will dictate
the success of vaccination. Thus, CpG ODN may be useful
as adjuvants to induce protective Th1 immunity.
In other circumstances the utility of CpG ODN may lie
in their potential ability to redirect pathogenic Th2 re-
sponses to less harmful Th1 responses. For example, Th2-
dominated responses appear to cause allergy, and recent
data suggest that administration of CpG ODN may prevent
or even reverse ongoing allergic reactions, presumably by
redirecting a Th2-dominated response to allergen (which
promotes IgE synthesis) to a Th1-dominated response
(Kline, J., T. Businga, T. Waldschmidt, J. Weinstock, and
A.M. Krieg, manuscript submitted for publication). Simi-
larly, autoimmune diseases that are potentially Th2-associ-
ated, such as systemic lupus erythematosis, may be amenable
to such Th1 therapy. Th1 therapy, however, is potentially
associated with the danger of inducing Th1-mediated pa-
thology, such as certain Th1-associated autoimmune diseases
(e.g., experimental allergic encephalomyelitis and type I in-
sulin dependent diabetes mellitus) (36).
The CpG motif has been proposed to act as a danger sig-
nal that warns of bacterial infection and activates immune
defenses (37). Similarly, one function of therapeutic adju-
vants may be to identify vaccine antigens as dangers to
which the immune system should respond. Thus, a danger
signal provided by CpG ODN may provide potent adju-
vant function. Our studies demonstrate that CpG ODN are1630 CpG DNA as a Th1 Adjuvant
extremely effective as adjuvants to induce Th1-dominated
immune responses without significant toxicity. This prop-
erty makes CpG ODN attractive as candidate adjuvants for
potential use in human vaccines for the prevention or treat-
ment of a wide range of infectious diseases and immune
disorders.
We thank Rob Fairchild, Neil Greenspan, Richard Trezza, and Hualin Yip for technical advice and helpful
discussion. John France provided technical assistance.
This work was supported by National Institutes of Health grants (AI35726, CA70149, and AI34343) to C.V.
Harding, NIH grant DK48799 to P.V. Lehmann, and grants from the NIH (AR42556 and CA66570) and
Department of Veterans Affairs to A.M. Kreig. R.S. Chu was supported by an NIH Medical Scientist Train-
ing Program grant (5T32 GM07250-21).
Address correspondence to Dr. Clifford V. Harding, Institute of Pathology, Case Western Reserve Univer-
sity, 2085 Adelbert Rd., Cleveland, OH 44106. Phone: (216) 368-4711; FAX: (216) 368-0495; E-mail:
cvh3@po.cwru.edu
Received for publication 8 May 1997 and in revised form 25 August 1997.
References
1. Abbas, A.K., K.M. Murphy, and A. Sher. 1996. Functional
diversity of helper T lymphocytes. Nature (Lond.). 383:787–793.
2. Mosmann, T.R., and R.L. Coffman. 1989. TH1 and TH2
cells: different patterns of lymphokine secretion lead to differ-
ent functional properties. Annu. Rev. Immunol. 7:145–173.
3. Seder, R.A., and W.E. Paul. 1994. Acquisition of lympho-
kine-producing phenotype by CD41 T cells. Annu. Rev. Im-
munol. 12:635–673.
4. Finkelman, F.D., J. Holmes, I.M. Katona, J.F. Urban, M.P.
Beckmann, L.S. Park, K.A. Schooley, R.L. Coffman, T.R.
Mosmann, and W.E. Paul. 1990. Lymphokine control of in
vivo immunoglobulin isotype selection. Annu. Rev. Immunol.
8:303–333.
5. Kelso, A. 1995. Th1 and Th2 subsets: paradigms lost? Immu-
nol. Today. 16:374–379.
6. Forsthuber, T., H.C. Yip, and P.V. Lehmann. 1996. Induc-
tion of TH1 and TH2 immunity in neonatal mice. Science
(Wash. DC). 271:1728–1730.
7. Pisetsky, D.S. 1996. Immune activation by bacterial DNA: a
new genetic code. Immunity. 5:303–310.
8. Chace, J.H., N.A. Hooker, K.L. Midlenstein, A.M. Krieg,
and J.S. Cowdery. 1997. Bacterial DNA-induced NK cell
IFN-g production is dependent on macrophage secretion of
IL-12. Clin. Immunol. Immunopathol. In press.
9. Stacey, K.J., M.J. Sweet, and D.A. Hume. 1996. Macrophages
ingest and are activated by bacterial DNA. J. Immunol. 157:
2116–2122.
10. Yamamoto, S., T. Yamamoto, S. Shimada, E. Kuramoto, O.
Yano, T. Kataoka, and T. Tokunaga. 1992. DNA from bac-
teria, but not from vertebrates, induces interferons, activates
natural killer cells and inhibits tumor growth. Microbiol. Im-
munol. 36:983–997.
11. Ballas, Z.K., W.L. Rasmussen, and A.M. Krieg. 1996. Induc-
tion of NK activity in murine and human cells by CpG mo-
tifs in oligodeoxynucleotides and bacterial DNA. J. Immunol.
157:1840–1845.
12. Cowdery, J.S., J.H. Chace, A.-K. Yi, and A.M. Krieg. 1996.
Bacterial DNA induces NK cells to produce IFN-g in vivo
and increases the toxicity of lipopolysaccharides. J. Immunol.
156:4570–4575.
13. Halpern, M.D., R.J. Kurlander, and D.S. Pisetsky. 1996.
Bacterial DNA induces murine interferon-g production by
stimulation of interleukin-12 and tumor necrosis factor-a.
Cell. Immunol. 167:72–78.
14. Krieg, A.M., A.-K. Yi, S. Matson, T.J. Waldschmidt, G.A.
Bishop, R. Teasdale, G.A. Koretzky, and D.M. Klinman. 1995.
CpG motifs in bacterial DNA trigger direct B cell activation.
Nature (Lond.). 374:546–549.
15. Bird, A.P. 1986. CpG-rich islands and the function of DNA
methylation. Nature (Lond.). 321:209–213.
16. Klinman, D.M., A.-K. Yi, S.L. Beaucage, J. Conover, and
A.M. Krieg. 1996. CpG motifs present in bacterial DNA rap-
idly induce lymphocytes to secrete interleukin 6, interleukin
12, and interferon g. Proc. Natl. Acad. Sci. USA. 93:2879–
2883.
17. Sato, Y., M. Roman, H. Tighe, D. Lee, M. Corr, M.-D.
Nguyen, G.J. Silverman, M. Lotz, D.A. Carson, and E. Raz.
1996. Immunostimulatory DNA sequences necessary for ef-
fective intradermal gene immunization. Science (Wash. DC). 273:
352–354.
18. Raz, E., H. Tighe, Y. Sato, J.A. Dudler, M. Roman, S.L.
Swain, H.L. Spiegelberg, and D.A. Carson. 1996. Preferential
induction of a Th1 immune response and inhibition of spe-
cific IgE antibody formation by plasmid DNA immunization.
Proc. Natl. Acad. Sci. USA. 93:5141–5145.
19. Stein, C.A., C. Subasinghe, K. Shinozuka, and J.S. Cohen.
1988. Physiochemical properties of phosphorothioate oli-
godeoxynucleotides.  Nucleic Acids Res. 16:3209–3221.
20. Hsieh, C.S., S.E. Macatonia, A. O’Garra, and K.M. Murphy.
1995. T cell genetic background determines default T helper
phenotype development in vitro. J. Exp. Med. 181:713–721.
21. Ada, G., and A. Ramsay 1997. Immunopotentiation and the
selective induction of immune responses. In Vaccines, Vacci-
nation and the Immune Response. G. Ada and A. Ramsay,
editors. Lippincott-Raven, Philadelphia. 122–136.
22. Tokunaga, T., O. Yano, E. Kuramoto, Y. Kimura, T. Yama-
moto, T. Kataoka, and S. Yamamoto. 1992. Synthetic oligo-
nucleotides with particular base sequences from the cDNA
encoding proteins of Mycobacterium bovis BCG induce inter-
ferons and activate natural killer cells. Microbiol. Immunol. 36:1631 Chu et al.
55–66.
23. Yamamoto, S., T. Yamamoto, T. Kataoka, E. Kuramoto, O.
Yano, and T. Tokunaga. 1992. Unique palindromic se-
quences in synthetic oligonucleotides are required to induce
INF and augment INF-mediated natural killer activity. J. Im-
munol. 148:4072–4076.
24. Monteith, D.K., S.P. Henry, R.B. Howard, S. Flournoy,
A.A. Levin, C.F. Bennett, and S.T. Crooke. 1997. Immune
stimulation—a class effect of phosphorothioate oligodeoxy-
nucleotides in rodents. Anticancer Drug Design. In press.
25. Bliss, J., V. Van Cleave, K. Murray, A. Wiencis, M. Ketchum,
R. Maylor, T. Haire, C. Resmini, A.K. Abbas, and S.F.
Wolf. 1996. IL-12, as an adjuvant, promotes a T helper 1
cell, but does not suppress a T helper 2 cell recall response. J.
Immunol. 156:887–894.
26. Sparwasser, T., T. Miethke, G. Lipford, K. Borschert, H.
Hæcker, K. Heeg, and H. Wagner. 1997. Bacterial DNA
causes septic shock. Nature (Lond.). 386:336–337.
27. Sarmiento, U.M., J.R. Perez, J.M. Becker, and R. Naray-
anan. 1994. In vivo toxicological effects of rel A antisense
phosphorothioates in CD-1 mice. Antisense Res. Dev. 4:99–107.
28. Finkelman, F.D. 1995. Relationships among antigen presen-
tation, cytokines, immune deviation, and autoimmune dis-
ease. J. Exp. Med. 182:279–282.
29. Reiner, S.L., and R.M. Locksley. 1995. The regulation of
immunity to Leishmania major. Annu. Rev. Immunol. 13:151–177.
30. Heinzel, F.P., M.D. Sadick, B.J. Holaday, R.L. Coffman, and
R.M. Locksley. 1989. Reciprocal expression of interferon g
or interleukin 4 during the resolution or progression of mu-
rine leishmaniasis. Evidence for expansion of distinct helper
T cell subsets. J. Exp. Med. 169:59–72.
31. Scott, P., P. Natovitz, R.L. Coffman, E. Pearce, and A. Sher.
1988. Immunoregulation of cutaneous leishmaniasis. T cell lines
that transfer protective immunity or exacerbation belong to
different T helper subsets and respond to distinct parasite an-
tigens. J. Exp. Med. 168:1675–1684.
32. Sadick, M.D., F.P. Heinzel, B.J. Holaday, R.T. Pu, R.S.
Dawkins, and R.M. Locksley. 1990. Cure of murine leish-
maniasis with anti-interleukin 4 monoclonal antibody. J.
Exp. Med. 171:115–127.
33. Heinzel, F.P., D.S. Schoenhaut, R.M. Rerko, L.E. Rosser,
and M.K. Gately. 1993. Recombinant interleukin 12 cures
mice infected with Leishmania major. J. Exp. Med. 177:1505–
1509.
34. Sypek, J.P., C.L. Chung, S.E.H. Mayor, J.M. Subramanyam,
S.J. Goldman, D.S. Sieburth, S.F. Wolf, and R.G. Schaub.
1993. Resolution of cutaneous leishmaniasis: interleukin 12
initiates a protective T helper type 1 immune response. J.
Exp. Med. 177:1797–1802.
35. Heinzel, F.P., R.M. Rerko, F. Ahmed, and E. Pearlman.
1995. Endogenous IL-12 is required for control of Th2 cy-
tokine responses capable of exacerbating leishmaniasis in nor-
mally resistant mice. J. Immunol. 155:730–739.
36. Liblau, R.S., S.M. Singer, and H.O. McDevitt. 1995. Th1
and Th2 CD41 T cells in the pathogenesis of organ-specific
autoimmune diseases. Immunol. Today. 16:34–38.
37. Krieg, A.M. 1996. Lymphocyte activation by CpG dinucle-
otide motifs in prokaryotic DNA. Trends Microbiol. 4:73–77.